After Hours Summary: ZUMZ +13% following SSS/guidance, semi/tech names higher following upside Dialog Semi sales... YUM -2.2% following earnings/guidance
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance/SSS: ALQA +27.4% (also announced plans to acquire the business of Soluble Systems), ZUMZ +13% (reports September same store sales +6.3% vs -1.8% September last year and -1.5% last month; raising Q3 EPS and sales guidance above consensus)
Companies trading higher in after hours in reaction to news: PHMD +21.7% (PhotoMedex to sell its consumer products business to ICTV Brands for $9.5 mln), SCYX +16.7% (announces complete results from two phase 2 Studies of Oral SCY-078 in patients with candida spp. infections; study results confirm overall antifungal activity of oral SCY-078 in patients with candida infections), JD +5.5% (Wal-Mart increases passive stake), SMTC +1.8% (Semtech confirms agreement with Comcast to deploy trial LoRaWAN network in the United States, deal provides warrant for Comcast to acquire up to $30 mln of common stock; co updates Q3 guidance as a result), MET +1.1% (confirms that Brighthouse Financial filed a Registration Statement on Form 10 with the SEC), AA +0.8% (completes 1:3 reverse stock split, shares to begin trading on split-adjusted basis tomorrow morning)
Semiconductor/tech names higher following upside Dialog Semi sales: AVGO +0.6%, NXPI +0.5%, QCOM +0.4%, AAPL +0.3% (higher on Dialog Semi upside sales guidance),
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: RECN -3.1% (also Anthony Cherbak announces his retirement as President and Chief Executive Officer due to health considerations), YUM -2.2%
Companies trading lower in after hours in reaction to news: ALNY -42.3% (to discontinue Revusiran development, says decision does not impact Patisiran or any other RNAi therapeutic program in development), IDRA -11.9% (commences $50 mln common stock offering), MDCO -11.7% (updates on the ongoing ORION-1 study of PCSK9si; anticipates that top-line data from Day 180 follow-up for up to 200 patients will be presented at the Late-Breaking Clinical Trial Session), IONS -3.9% and ARWR -3.6% (ALNY sympathy), VRA -0.7% (lower on light volume following downgrade at KeyBanc)